middle.news

ReNerve Surges with 260% Sales Growth and Expands Into Asia and Middle East

7:03pm on Monday 2nd of June, 2025 AEST Biotechnology
Read Story

ReNerve Surges with 260% Sales Growth and Expands Into Asia and Middle East

7:03pm on Monday 2nd of June, 2025 AEST
Key Points
  • 260% sales growth in Q2 FY25 compared to prior year
  • Raised A$7 million in heavily oversubscribed IPO at $0.20 per share
  • Exclusive distribution agreements secured in Hong Kong, Macau, and Middle East
  • Clinical study results for NervAlign® Nerve Cuff expected late Q3 FY25
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Renerve (ASX:RNV)
OPEN ARTICLE